Polymeric Nanoparticles Revolutionizing Brain Cancer Therapy: A Comprehensive Review of Strategies and Advances DOI

Gilchrist Singh Wahengbam,

Sakshi Nirmal,

Jai Nandwana

et al.

Critical Reviews in Therapeutic Drug Carrier Systems, Journal Year: 2024, Volume and Issue: 42(2), P. 73 - 106

Published: Nov. 15, 2024

Brain cancer continues to be one of the most formidable malignancies manage, mainly attributable presence blood-brain barrier (BBB) limiting permeability drugs and diverse characteristics brain tumors complicating treatment. The management has been hampered by many different factors, including impermeability BBB, which restricts delivery chemotherapeutic agents tumor site, as well intertumoral heterogeneity influence stem cells. In addition, small molecular weight cannot specifically accumulate in malignant cells have a limited circulation half-life. Nanoparticles (NPs) can engineered traverse BBB transport therapeutic medications directly into brain, enhancing their efficacy compared with conventional unbound drugs. Surface modifications NPs boost efficiency increasing selectivity towards receptors. This review covers treatment methods for gliomas, associated risk improvements drug administration, emphasizing future potential polymeric mechanism crossing BBB. To surmount these obstacles, newly formulated drug-delivery approach utilizing NPs, particularly those coated cell membranes, demonstrated treating cancer. These provide targeted specificity, biocompatibility, extended circulation, enhanced penetration, immune evasion. focuses on coating strategies PLGA dual-targeting methods, enhance tumor-targeted

Language: Английский

Protein-based nano delivery systems focusing on protein materials, fabrication strategies and applications in ischemic stroke intervention: A review DOI
Chao Yan, Xiang Zhu, Yingying Ren

et al.

International Journal of Biological Macromolecules, Journal Year: 2025, Volume and Issue: 311, P. 143645 - 143645

Published: April 29, 2025

Language: Английский

Citations

0
Modulation of antibody transport in the brain and spinal cord through the intranasal pathway DOI Creative Commons

Sebastian Spiegel,

Sandrine Joly,

Ivo Meli

et al.

Neurotherapeutics, Journal Year: 2025, Volume and Issue: unknown, P. e00606 - e00606

Published: May 1, 2025

The intranasal pathway is a promising antibody delivery route for the treatment of neurological diseases, but mechanisms mediating nose-to-brain/spinal cord transport are poorly understood. aim our study was to determine if antibodies can pharmacologically be modulated in mouse CNS. pharmacokinetics and distribution recombinant were followed brain spinal homogenates biofluids by ELISA immunofluorescence. A non-CNS antigen-binding (FG12) used monitor target-independent whereas 11C7 mAb, neutralizing myelin-associated growth inhibitor Nogo-A, applied induce CNS target-dependent neuronal response. Fast axonal transport/neuronal activity inhibited with Lidocaine pre-treatment on olfactory mucosa. Antibody uptake enhanced across epithelium co-administration cell-penetrating peptide Penetratin. Growth signalling pathways examined Western blotting. FG12 detected as early 30 ​min after administration. After 1 ​h, concentration rapidly declined all areas back baseline values at 24 ​h. prevented rise cord. This effect not observed brain. Penetratin allowed maintain elevation activate 11C7-induced Our data suggest that pharmacological modulation nose-to-CNS may allow control therapeutic effects diseases.

Language: Английский

Citations

0
Nanotechnology-Enhanced siRNA Delivery: Revolutionizing Cancer Therapy DOI
Donya Esmaeilpour, Matineh Ghomi, Ehsan Nazarzadeh Zare‬

et al.

ACS Applied Bio Materials, Journal Year: 2025, Volume and Issue: unknown

Published: May 12, 2025

RNA interference (RNAi) has emerged as a transformative approach for cancer therapy, enabling precise gene silencing through small interfering (siRNA). However, the clinical application of siRNA-based treatments faces challenges such rapid degradation, inefficient cellular uptake, and immune system clearance. Nanotechnology-enhanced siRNA delivery revolutionized therapy by addressing these limitations, improving stability, tumor-specific targeting, therapeutic efficacy. Recent advancements in nanocarrier engineering have introduced innovative strategies to enhance safety precision therapies, offering new opportunities personalized medicine. This review highlights three key innovations nanotechnology-enhanced delivery: artificial intelligence (AI)-driven design, multifunctional nanoparticles combined strategies, biomimetic nanocarriers enhanced biocompatibility. AI-driven utilize machine learning algorithms optimize nanoparticle properties, drug release profiles minimizing off-target effects. Multifunctional integrate with chemotherapy, immunotherapy, or photothermal synergistic treatment approaches that outcomes reduce resistance. Biomimetic nanocarriers, including exosome-mimicking systems cell-membrane-coated nanoparticles, improve circulation time, evasion, targeted tumor delivery. These collectively precision, efficiency, therapies. The scope novelty lie their ability overcome primary barriers while paving way clinically viable solutions. provides comprehensive analysis latest developments fabrication, preclinical studies, assessments. By integrating multifunctionality, biomimicry, holds immense potential future therapy.

Language: Английский

Citations

0
Unlocking the Gates: Therapeutic Agents for Noninvasive Drug Delivery Across the Blood-Brain Barrier DOI

Courtney Culkins,

Roman Adomanis,

Nathan Phan

et al.

Molecular Pharmaceutics, Journal Year: 2024, Volume and Issue: unknown

Published: Sept. 26, 2024

The blood-brain barrier (BBB) is a highly selective network of various cell types that acts as filter between the blood and brain parenchyma. Because this, BBB remains major obstacle for drug delivery to central nervous system (CNS). In recent years, there has been focus on developing modifiable platforms, such monoclonal antibodies (mAbs), nanobodies (Nbs), peptides, nanoparticles, both therapeutic agents carriers targeted treat cancers diseases. Methods bypassing can be invasive or noninvasive. Invasive techniques, transient disruption using low pulse electrical fields intracerebroventricular infusion, lack specificity have numerous safety concerns. this review, we will noninvasive transport mechanisms offer high levels biocompatibility, personalization, are regarded generally safer than their counterparts. Modifiable platforms designed noninvasively traverse through one more following pathways: passive diffusion physio-pathologically disrupted BBB, adsorptive-mediated transcytosis, receptor-mediated shuttle-mediated somatic gene transfer. Through understanding pathways, new applications, including Chimeric Antigen Receptors T-cell (CAR-T) therapy, approaches across emerging.

Language: Английский

Citations

2
Mechanics of poly-arginine adsorption onto cell membrane by GM1 and their cluster forming: coarse-grained molecular dynamics study DOI
Yongkang Lyu,

Yonglin Cui,

Xiaolin Chen

et al.

Journal of Molecular Structure, Journal Year: 2024, Volume and Issue: 1322, P. 140690 - 140690

Published: Nov. 9, 2024

Language: Английский

Citations

2
Polymeric Nanoparticles Revolutionizing Brain Cancer Therapy: A Comprehensive Review of Strategies and Advances DOI

Gilchrist Singh Wahengbam,

Sakshi Nirmal,

Jai Nandwana

et al.

Critical Reviews in Therapeutic Drug Carrier Systems, Journal Year: 2024, Volume and Issue: 42(2), P. 73 - 106

Published: Nov. 15, 2024

Brain cancer continues to be one of the most formidable malignancies manage, mainly attributable presence blood-brain barrier (BBB) limiting permeability drugs and diverse characteristics brain tumors complicating treatment. The management has been hampered by many different factors, including impermeability BBB, which restricts delivery chemotherapeutic agents tumor site, as well intertumoral heterogeneity influence stem cells. In addition, small molecular weight cannot specifically accumulate in malignant cells have a limited circulation half-life. Nanoparticles (NPs) can engineered traverse BBB transport therapeutic medications directly into brain, enhancing their efficacy compared with conventional unbound drugs. Surface modifications NPs boost efficiency increasing selectivity towards receptors. This review covers treatment methods for gliomas, associated risk improvements drug administration, emphasizing future potential polymeric mechanism crossing BBB. To surmount these obstacles, newly formulated drug-delivery approach utilizing NPs, particularly those coated cell membranes, demonstrated treating cancer. These provide targeted specificity, biocompatibility, extended circulation, enhanced penetration, immune evasion. focuses on coating strategies PLGA dual-targeting methods, enhance tumor-targeted

Language: Английский

Citations

1